News | March 28, 2022
Aurobindo enters domestic formulations space with the acquisition of Veritaz for Rs 171 Cr
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
The facility will manufacture its Herceptin biosimilar, Tuznue
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Subscribe To Our Newsletter & Stay Updated
